Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Curr Opin Oncol. 2020 Sep;32(5):481–487. doi: 10.1097/CCO.0000000000000663

Figure 1.

Figure 1.

Dramatic response to therapy with the combination of ipilimumab and nivolumab on CHECKMATE 358. CT scans at baseline, 2 months, and 1 year of therapy. The patient remains without disease >12 months after completing two years of immunotherapy. Images © per the authors.